Replimune

News

Replimune has announced the FDA has issued a Complete Response Letter regarding the Biologics License Application for RP1 combined with nivolumab.

Oncology

At Reuters Pharma USA this week, Boehringer Ingelheim's Vicky Brown spoke with us about the company's recent approval for Hernexeos in NSCLC.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.